2015 American Transplant Congress
The Use of Eculizumab to Treat the Highly Sensitized Patient Awaiting Heart Transplant
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: Highly sensitized patients (pts) awaiting heart transplantation remain a significant challenge due to prolonged often prohibitive wait times for suitable organs and increased rejection…2015 American Transplant Congress
Everolimus Versus Mycophenolate for Recipients of Kidney Transplants from Expanded Criteria Donors (ECD) Receiving Anti-Thymocyte Globulin and Tacrolimus
Introduction: Recipients of kidneys recovered from expanded criteria donors are at higher risk to develop delayed graft function (DGF) and acute rejection (AR), leading to…2015 American Transplant Congress
CD28-Directed Therapy Prolongs Survival in a Non-Human Primate Kidney Transplant Model
Introduction. Costimulation blockade using belatacept has the potential to improve long-term renal function and reduce cardiovascular risk by avoiding calcineurin inhibitors, yet higher rates and…2015 American Transplant Congress
A Novel Maintenance Regimen With Calcineurin Inhibitor, MMF and Everolimus Initiated By Dual Induction Therapy With Anti-CD20/25 Antibodies in Renal Transplantation
Surgery III, Tokyo Women's Medical University Hospital, Shinjuku-ku,Tokyo, Japan.
【background】Calcineurin inhibitor (CNI), MMF and steroid has been the gold standard of maintenance regimen in renal transplantation (RTx). A line of new immunosuppressants has emerged…2015 American Transplant Congress
microRNA-494 Promotes Cyclosporine-Induced Nephrotoxicity and Epithelial to Mesenchymal Transition By Inhibiting PTEN
Purpose: A major complication associated with cyclosporine (CsA) treatment is nephrotoxicity. MicroRNAs (miRs) have been shown to play an important role in various pathological conditions,…2015 American Transplant Congress
Evaluation of Medication Regimen Complexity Over Time Following Heart Re-Transplantation
Medication regimen complexity (MRC) includes many characteristics of a drug regimen. Previously, we showed that MRC is high and persists over time after primary heart…2015 American Transplant Congress
Kidney Transplant Function After Late Conversion to Belatacept (Nulojix®)
Introduction: In the long-term follow up of kidney transplants, chronic transplant nephropathy often in combination with CNI-toxicity is a major problem. With declining transplant function…2015 American Transplant Congress
No Pharmacokinetic Interaction Between Pantoprazole and Mycophenolic Acid in Renal Transplant Patents: A Randomized Crossover Study
Department of Nephrology, Charité University Hospital, Berlin, Germany.
Mycophenolic acid (MPA) is used as an immunosuppressive agent in renal transplant (tx) patients (pts). 2 formulations are on the market: The prodrug Mycophenolate-Mofetil (MMF)…2015 American Transplant Congress
Patient Self-Reported Adherence to and Perceptions Towards Immunosuppressive Medications at the Outpatient Renal Transplant Clinic at St. Joseph's Healthcare Hamilton (SJHH)
Objectives To gain insight into the immunosuppressant adherence of patients followed by the Outpatient Renal Transplant Clinic at St. Joseph's Healthcare Hamilton (SJHH) and to…2015 American Transplant Congress
CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment
Background: T-cell depleting strategies have become an integral part of immunosuppressive regimens in organ transplantation. Alemtuzumab is a humanized monoclonal antibody against CD52, a cell-surface…
American Transplant Congress abstracts